AYTU BIOPHARMA, INC Operating Leases, Rent Expense
AYTU BIOPHARMA, INC (AYTU) reported Operating Leases, Rent Expense of $70.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2020-11-12
- AYTU BIOPHARMA, INC operating leases, rent expense for the quarter ending 2020-09-30 was $70.00K, a 118.75% increase year-over-year.
- AYTU BIOPHARMA, INC operating leases, rent expense for the quarter ending 2020-06-30 was $74.00K, a 1133.33% increase year-over-year.
- AYTU BIOPHARMA, INC operating leases, rent expense for the quarter ending 2020-03-31 was $61.00K, a 96.77% increase year-over-year.
- AYTU BIOPHARMA, INC operating leases, rent expense for the quarter ending 2019-12-31 was $30.00K, a 3.23% decline year-over-year.
- AYTU BIOPHARMA, INC operating leases, rent expense for fiscal 2020 was $200.00K, a 100.00% increase from fiscal 2019.
- AYTU BIOPHARMA, INC operating leases, rent expense for fiscal 2019 was $100.00K.
- AYTU BIOPHARMA, INC operating leases, rent expense for fiscal 2015 was $112.00K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2020-09-30 | $70.00K 10-Q · filed 2020-11-12 | $144.00K derived: sum of 2 quarters · filed 2020-11-12 | $205.00K derived: sum of 3 quarters · filed 2020-11-12 | $235.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2020-06-30 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $135.00K derived: sum of 2 quarters · filed 2020-10-06 | $165.00K derived: sum of 3 quarters · filed 2020-10-06 | $200.00K 10-K · filed 2020-10-06 |
| 2020-03-31 | $61.00K 10-Q · filed 2020-05-15 | $91.00K derived: sum of 2 quarters · filed 2020-05-15 | $126.00K 10-Q · filed 2020-05-15 | $129.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-12-31 | $30.00K 10-Q · filed 2020-02-14 | $63.00K 10-Q · filed 2020-02-14 | $68.00K derived: sum of 3 quarters · filed 2020-11-12 | $99.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-09-30 | $32.00K 10-Q · filed 2020-11-12 | $38.00K derived: sum of 2 quarters · filed 2020-11-12 | $69.00K derived: sum of 3 quarters · filed 2020-11-12 | $100.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06 | $37.00K derived: sum of 2 quarters · filed 2020-10-06 | $68.00K derived: sum of 3 quarters · filed 2020-10-06 | $100.00K 10-K · filed 2020-10-06 |
| 2019-03-31 | $31.00K 10-Q · filed 2020-05-15 | $62.00K derived: sum of 2 quarters · filed 2020-05-15 | $94.00K 10-Q · filed 2020-05-15 | |
| 2018-12-31 | $31.00K 10-Q · filed 2020-02-14 | $63.00K 10-Q · filed 2020-02-14 | ||
| 2018-09-30 | $32.00K 10-Q · filed 2019-11-14 | |||
| 2015-06-30 | $112.00K 10-K · filed 2015-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |